Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

ASCO: Keytruda Inches Uncertainly Towards Tecentriq In Triple-Negative Breast Cancer

KEYNOTE-355 Mixed On PFS; Still Waiting On OS

May 19 2020

• By Eleanor Malone

Dividing breast cancer cell

Related Content

Roche's Tecentriq Notches Approval For First-Line NSCLC Monotherapy

May 19 2020

Keytruda Closing In On First-Line Metastatic Triple-Negative Breast Cancer

Feb 13 2020

Related Companies

Merck & Co., Inc.

Roche Holding AG

Additional Topics

Clinical Trials ImmunoOncology Research & Development ASCO Cancer BioPharmaceutical

More from ASCO

More from Conferences

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.